Specialized Peptide-based Vaccination Solutions for Niche Environments
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts peptide-based vaccination technology for specific, high-need environments, including disaster relief, high-security facilities, extreme weather conditions, high-altitude environments, and remote areas.
Background and Problem Solved
The original patent disclosed peptide-based vaccination technology for antimicrobial prophylaxis and therapy. However, it did not address the unique challenges and requirements of vaccination in specialized environments. This inventive concept addresses these limitations by providing tailored solutions for niche markets.
Detailed Description of the Inventive Concept
The inventive concept comprises four specialized variations of the original peptide-based vaccination technology. Firstly, a method for disaster relief vaccination involves administering the pharmaceutical composition in a post-disaster setting to immunize against Acinetobacter baumannii infections. Secondly, a system for high-security vaccination features a secure storage unit for storing the composition in a high-security facility. Thirdly, a pharmaceutical composition for extreme weather vaccination is formulated to withstand extreme temperatures. Lastly, methods for vaccination in high-altitude environments and remote areas involve formulating the composition to withstand low oxygen levels and using portable storage units, respectively.
Novelty and Inventive Step
The new claims introduce novel and non-obvious adaptations of the original peptide-based vaccination technology for specific, high-need environments. These adaptations involve unique formulations, storage solutions, and administration methods tailored to the requirements of each environment.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include adaptations for other niche environments, such as space exploration, military operations, or emergency response situations. Variations could also involve different peptide sequences, adjuvants, or carriers tailored to specific environments or applications.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the vaccination market, particularly in niche areas such as disaster relief, high-security facilities, extreme weather conditions, high-altitude environments, and remote areas. Target industries could include government agencies, private security companies, and humanitarian organizations.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/104 |
| C | C07 | C07K14/212 |
| A | A61 | A61K2039/543 |
| A | A61 | A61K2039/55505 |
| A | A61 | A61K2039/55566 |
| G | G01 | G01N2333/22 |
| G | G01 | G01N2469/20 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and pharmaceutical vaccine development, specifically focused on peptide-based immunological compositions for infectious disease prevention, with expertise in microbial protein engineering, vaccine formulation, and specialized delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with advanced degrees in microbiology or biotechnology, experienced in vaccine design, protein modification, and understanding environmental adaptation strategies for pharmaceutical compositions
Obviousness Rationale
A person having ordinary skill would recognize that adapting the Acinetobacter baumannii peptide vaccine to specialized environments represents predictable variations within standard vaccine development practices. The core peptide composition remains substantially unchanged, with modifications focusing on delivery, storage, and environmental resilience. These adaptations represent routine engineering solutions that would be apparent to a skilled practitioner seeking to expand vaccine utility across challenging contexts.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,615 |
|---|---|
| Title | Peptides derived from Acinetobacter baumannii and their use in vaccination |
| Assignee(s) | Evaxion Biotech A/S |